Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe

Current Medical Research and Opinion
R K CadyCharlotte Keywood

Abstract

To evaluate whether frovatriptan would provide greater relief if given early during a migraine attack. Adults with a history of migraine of at least 1 year, and who had 2-8 headaches in the previous month were recruited from 19 US centres for a prospective, placebo-controlled crossover study over 2 migraine attacks. Dose 1 was taken at the onset of mild migraine headache, Dose 2 was taken at least 2 h later if the headache progressed to moderate/severe. Patients were randomized to receive Dose 1 frovatriptan then Dose 2 placebo or Dose 1 placebo followed by Dose 2 frovatriptan. Treatment order was reversed for the second attack. This schedule enabled a comparison of frovatriptan with placebo and a comparison of early and later treatment with frovatriptan. Freedom from pain at 2 h for frovatriptan versus placebo as Dose 1; use of Dose 2 and/or rescue medication, pain severity, functional impairment and headache recurrence. In 241 patients who each treated 2 migraine attacks, Dose 1 frovatriptan was more effective than placebo in terms of the proportion of patients who were pain free at 2 h (28% vs 20%, p = 0.04). This benefit was sustained up to 4 h post-dose (p = 0.003). Early use of frovatriptan significantly reduced re-medica...Continue Reading

References

Apr 29, 1999·Archives of Internal Medicine·X H HuM L Berger
May 25, 2002·Headache·Alan RapoportCharlotte Keywood
Nov 28, 2002·Headache·Michael T HalpernAlice S Batenhorst

❮ Previous
Next ❯

Citations

May 6, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Gianni AllaisGennaro Bussone
Dec 14, 2005·Current Treatment Options in Neurology·Robert Kaniecki
Feb 14, 2006·Cephalalgia : an International Journal of Headache·P SarchielliP Calabresi
Sep 6, 2008·Cephalalgia : an International Journal of Headache·A Gendolla
Jan 20, 2010·Cephalalgia : an International Journal of Headache·D Valade
Jun 30, 2006·International Journal of Clinical Practice·A J DowsonJ Pascual
Aug 30, 2008·Neuropsychiatric Disease and Treatment·Leslie Kelman
Oct 12, 2010·The Journal of Headache and Pain·Anders Hougaard, Peer Tfelt-Hansen
Feb 16, 2007·Headache·Ninan T MathewUNKNOWN AEGIS Investigator Study Group
May 31, 2006·Headache·Roger CadyFranck Skobieranda
Dec 13, 2005·Journal of Clinical Pharmacy and Therapeutics·N PoolsupM Khanthong
May 7, 2008·Expert Review of Neurotherapeutics·Arthur H Elkind, E Anne MacGregor
Jul 13, 2006·Expert Review of Neurotherapeutics·Domenico D'AmicoGennaro Bussone
Nov 16, 2007·Expert Opinion on Pharmacotherapy·Färkkilä Markus, Kallela Mikko
Jul 25, 2006·Expert Opinion on Pharmacotherapy·Roger Cady, Curtis Schreiber
Apr 29, 2015·The Journal of Headache and Pain·Stefan EversLorenzo Pinessi
Nov 12, 2005·Journal of Occupational and Environmental Medicine·W Jacqueline KwongJames U Adelman
Apr 1, 2021·Current Medical Research and Opinion·Mario F P PeresDeborah I Friedman
Jul 11, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Johra KhanJ Francis Borgio

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.